Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma

医学 肝细胞癌 内科学 乙型肝炎病毒 丙型肝炎病毒 抗病毒治疗 队列 胃肠病学 乙型肝炎 丙型肝炎 肿瘤科 病毒 免疫学 慢性肝炎
作者
Daniel Q. Huang,Joseph Hoang,Rubayet Kamal,Pei‐Chien Tsai,Hidenori Toyoda,Ming‐Lun Yeh,Satoshi Yasuda,Jennifer Leong,Mayumi Maeda,Chung‐Feng Huang,Dae Won Jun,Masatoshi Ishigami,Yasuhito Tanaka,Haruki Uojima,Eiichi Ogawa,Hiroshi Abe,Yao‐Chun Hsu,Cheng‐Hao Tseng,Manaf Alsudaney,Ju Dong Yang,Yoko Yoshimaru,Takanori Suzuki,Joanne K. Liu,Charles Landis,Chia‐Yen Dai,Jee‐Fu Huang,Wan‐Long Chuang,Myron Schwartz,Yock Young Dan,Carlos O. Esquivel,Andrew Bonham,Ming‐Lung Yu,Mindie H. Nguyen
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (7): 790-799 被引量:12
标识
DOI:10.1200/jco.23.00757
摘要

PURPOSE There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)– and hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS The mean (±standard deviation [SD]) age was 62.1 (±11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (±SD) follow-up of 5.0 (±4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
毛豆爸爸应助violetyjm采纳,获得20
2秒前
2秒前
2秒前
2秒前
He发布了新的文献求助10
3秒前
3秒前
子铭完成签到,获得积分10
3秒前
Owen应助马某某某某某采纳,获得10
4秒前
song发布了新的文献求助10
5秒前
布丁完成签到 ,获得积分10
7秒前
7秒前
7秒前
XIE发布了新的文献求助50
8秒前
zz发布了新的文献求助10
9秒前
毛豆爸爸应助violetyjm采纳,获得20
10秒前
李朝富发布了新的文献求助10
10秒前
心随以动发布了新的文献求助10
10秒前
11秒前
Cao完成签到 ,获得积分10
12秒前
genomed应助愫问采纳,获得20
13秒前
郑岩狭完成签到 ,获得积分10
13秒前
优雅雁菱完成签到,获得积分10
13秒前
14秒前
15秒前
Singularity发布了新的文献求助10
16秒前
16秒前
毛豆爸爸应助violetyjm采纳,获得20
18秒前
积极南珍发布了新的文献求助100
18秒前
收入股发布了新的文献求助10
18秒前
19秒前
科目三应助Meimei采纳,获得20
19秒前
111111111发布了新的文献求助10
20秒前
20秒前
大模型应助李朝富采纳,获得10
20秒前
22秒前
danrushui777发布了新的文献求助30
22秒前
23秒前
方塘发布了新的文献求助30
23秒前
23秒前
炒栗子发布了新的文献求助10
25秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139127
求助须知:如何正确求助?哪些是违规求助? 2790013
关于积分的说明 7793363
捐赠科研通 2446416
什么是DOI,文献DOI怎么找? 1301093
科研通“疑难数据库(出版商)”最低求助积分说明 626106
版权声明 601102